United Therapeutics Corporation (UTHR)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	1,195,100	1,110,900	1,069,400	1,050,500	984,800	899,800	871,500	728,300	727,300	707,400	630,800	687,400	475,800	462,400	470,900	405,400	514,800	468,600	429,800	527,800
Total stockholders’ equity	US$ in thousands	6,444,000	6,100,900	5,697,200	5,338,100	5,984,800	5,712,100	5,411,000	5,123,200	4,796,700	4,562,200	4,318,400	4,176,300	3,958,900	3,829,700	3,639,500	3,445,400	3,395,200	3,283,100	3,093,700	2,948,500
ROE		18.55%	18.21%	18.77%	19.68%	16.46%	15.75%	16.11%	14.22%	15.16%	15.51%	14.61%	16.46%	12.02%	12.07%	12.94%	11.77%	15.16%	14.27%	13.89%	17.90%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,195,100K ÷ $6,444,000K
= 18.55%

United Therapeutics Corporation's Return on Equity (ROE) has shown fluctuation over the past few years, ranging between 11.77% to 19.68%. Generally, a higher ROE indicates that a company is generating more profit with the equity it has, which is favorable for shareholders.

The ROE of United Therapeutics Corporation has been relatively healthy, with values consistently above 10%, reflecting efficient utilization of shareholder equity to generate profits. The upward trend from 11.77% in March 2021 to 19.68% in March 2024 is a positive sign, indicating the company's improving ability to generate profits from its equity base.

Despite some fluctuations, United Therapeutics Corporation has maintained a stable ROE above 10% over the period under review, suggesting a solid performance in terms of generating returns for its shareholders. Investors typically look for companies with a consistent and healthy ROE, which United Therapeutics Corporation seems to be demonstrating.